Hypoxia-inducible gene expression system using the erythropoietin enhancer and 3′-untranslated region for the VEGF gene therapy

Minhyung Lee, Donghoon Choi, Min Ji Choi, Ji Hoon Jeong, Won Jong Kim, Seungjoon Oh, Yong Hee Kim, David A. Bull, Sung Wan Kim

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Gene therapy with the vascular endothelial growth factor (VEGF) gene is a potential treatment for many disorders or injuries with ischemia. However, unregulated expression of VEGF may induce pathological angiogenesis, promoting tumor growth, diabetic proliferative retinopathy and rupture of atherosclerotic plaque. Therefore, the effective regulation of the gene expression is one of the requirements for the VEGF gene therapy. In this research, we evaluated the hypoxia-inducible gene expression system with the erythropoietin (Epo) enhancer and the Epo 3′-untranslated region (UTR). The luciferase plasmids were constructed with the Epo enhancer (pEpo-SV-Luc), the Epo 3′-UTR (pSV-Luc-EpoUTR) or both (pEpo-SV-Luc-EpoUTR). The polyethylenimine/plasmid complexes were transfected to 293 or A7R5 cells and the cells were incubated under normoxia or hypoxia. The results showed that the Epo enhancer or Epo 3′-UTR increased the target gene expression under hypoxia. pEpo-SV-Luc-EpoUTR showed the highest luciferase expression. The VEGF expression plasmid with the Epo enhancer and 3′-UTR was also constructed. The VEGF expression by pEpo-SV-VEGF-EpoUTR showed the highest specificity of the gene expression in the hypoxic cells. The results suggest that the VEGF plasmid with the Epo enhancer and the Epo 3′-UTR may be useful for gene therapy for ischemic diseases.

Original languageEnglish
Pages (from-to)113-119
Number of pages7
JournalJournal of Controlled Release
Volume115
Issue number1
DOIs
Publication statusPublished - 2006 Sep 28

Fingerprint

3' Untranslated Regions
Erythropoietin
Genetic Therapy
Vascular Endothelial Growth Factor A
Gene Expression
Plasmids
Luciferases
Pathologic Neovascularization
Hypoxia
Polyethyleneimine
Gene Expression Regulation
Diabetic Retinopathy
Atherosclerotic Plaques
Rupture
Ischemia
Wounds and Injuries
Growth
Research

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Lee, Minhyung ; Choi, Donghoon ; Choi, Min Ji ; Jeong, Ji Hoon ; Kim, Won Jong ; Oh, Seungjoon ; Kim, Yong Hee ; Bull, David A. ; Kim, Sung Wan. / Hypoxia-inducible gene expression system using the erythropoietin enhancer and 3′-untranslated region for the VEGF gene therapy. In: Journal of Controlled Release. 2006 ; Vol. 115, No. 1. pp. 113-119.
@article{ddc17a36c2514056a049e707d225e6c3,
title = "Hypoxia-inducible gene expression system using the erythropoietin enhancer and 3′-untranslated region for the VEGF gene therapy",
abstract = "Gene therapy with the vascular endothelial growth factor (VEGF) gene is a potential treatment for many disorders or injuries with ischemia. However, unregulated expression of VEGF may induce pathological angiogenesis, promoting tumor growth, diabetic proliferative retinopathy and rupture of atherosclerotic plaque. Therefore, the effective regulation of the gene expression is one of the requirements for the VEGF gene therapy. In this research, we evaluated the hypoxia-inducible gene expression system with the erythropoietin (Epo) enhancer and the Epo 3′-untranslated region (UTR). The luciferase plasmids were constructed with the Epo enhancer (pEpo-SV-Luc), the Epo 3′-UTR (pSV-Luc-EpoUTR) or both (pEpo-SV-Luc-EpoUTR). The polyethylenimine/plasmid complexes were transfected to 293 or A7R5 cells and the cells were incubated under normoxia or hypoxia. The results showed that the Epo enhancer or Epo 3′-UTR increased the target gene expression under hypoxia. pEpo-SV-Luc-EpoUTR showed the highest luciferase expression. The VEGF expression plasmid with the Epo enhancer and 3′-UTR was also constructed. The VEGF expression by pEpo-SV-VEGF-EpoUTR showed the highest specificity of the gene expression in the hypoxic cells. The results suggest that the VEGF plasmid with the Epo enhancer and the Epo 3′-UTR may be useful for gene therapy for ischemic diseases.",
author = "Minhyung Lee and Donghoon Choi and Choi, {Min Ji} and Jeong, {Ji Hoon} and Kim, {Won Jong} and Seungjoon Oh and Kim, {Yong Hee} and Bull, {David A.} and Kim, {Sung Wan}",
year = "2006",
month = "9",
day = "28",
doi = "10.1016/j.jconrel.2006.07.010",
language = "English",
volume = "115",
pages = "113--119",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

Hypoxia-inducible gene expression system using the erythropoietin enhancer and 3′-untranslated region for the VEGF gene therapy. / Lee, Minhyung; Choi, Donghoon; Choi, Min Ji; Jeong, Ji Hoon; Kim, Won Jong; Oh, Seungjoon; Kim, Yong Hee; Bull, David A.; Kim, Sung Wan.

In: Journal of Controlled Release, Vol. 115, No. 1, 28.09.2006, p. 113-119.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hypoxia-inducible gene expression system using the erythropoietin enhancer and 3′-untranslated region for the VEGF gene therapy

AU - Lee, Minhyung

AU - Choi, Donghoon

AU - Choi, Min Ji

AU - Jeong, Ji Hoon

AU - Kim, Won Jong

AU - Oh, Seungjoon

AU - Kim, Yong Hee

AU - Bull, David A.

AU - Kim, Sung Wan

PY - 2006/9/28

Y1 - 2006/9/28

N2 - Gene therapy with the vascular endothelial growth factor (VEGF) gene is a potential treatment for many disorders or injuries with ischemia. However, unregulated expression of VEGF may induce pathological angiogenesis, promoting tumor growth, diabetic proliferative retinopathy and rupture of atherosclerotic plaque. Therefore, the effective regulation of the gene expression is one of the requirements for the VEGF gene therapy. In this research, we evaluated the hypoxia-inducible gene expression system with the erythropoietin (Epo) enhancer and the Epo 3′-untranslated region (UTR). The luciferase plasmids were constructed with the Epo enhancer (pEpo-SV-Luc), the Epo 3′-UTR (pSV-Luc-EpoUTR) or both (pEpo-SV-Luc-EpoUTR). The polyethylenimine/plasmid complexes were transfected to 293 or A7R5 cells and the cells were incubated under normoxia or hypoxia. The results showed that the Epo enhancer or Epo 3′-UTR increased the target gene expression under hypoxia. pEpo-SV-Luc-EpoUTR showed the highest luciferase expression. The VEGF expression plasmid with the Epo enhancer and 3′-UTR was also constructed. The VEGF expression by pEpo-SV-VEGF-EpoUTR showed the highest specificity of the gene expression in the hypoxic cells. The results suggest that the VEGF plasmid with the Epo enhancer and the Epo 3′-UTR may be useful for gene therapy for ischemic diseases.

AB - Gene therapy with the vascular endothelial growth factor (VEGF) gene is a potential treatment for many disorders or injuries with ischemia. However, unregulated expression of VEGF may induce pathological angiogenesis, promoting tumor growth, diabetic proliferative retinopathy and rupture of atherosclerotic plaque. Therefore, the effective regulation of the gene expression is one of the requirements for the VEGF gene therapy. In this research, we evaluated the hypoxia-inducible gene expression system with the erythropoietin (Epo) enhancer and the Epo 3′-untranslated region (UTR). The luciferase plasmids were constructed with the Epo enhancer (pEpo-SV-Luc), the Epo 3′-UTR (pSV-Luc-EpoUTR) or both (pEpo-SV-Luc-EpoUTR). The polyethylenimine/plasmid complexes were transfected to 293 or A7R5 cells and the cells were incubated under normoxia or hypoxia. The results showed that the Epo enhancer or Epo 3′-UTR increased the target gene expression under hypoxia. pEpo-SV-Luc-EpoUTR showed the highest luciferase expression. The VEGF expression plasmid with the Epo enhancer and 3′-UTR was also constructed. The VEGF expression by pEpo-SV-VEGF-EpoUTR showed the highest specificity of the gene expression in the hypoxic cells. The results suggest that the VEGF plasmid with the Epo enhancer and the Epo 3′-UTR may be useful for gene therapy for ischemic diseases.

UR - http://www.scopus.com/inward/record.url?scp=33748788239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748788239&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2006.07.010

DO - 10.1016/j.jconrel.2006.07.010

M3 - Article

C2 - 16962197

AN - SCOPUS:33748788239

VL - 115

SP - 113

EP - 119

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -